Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Return on Sales (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Return on Sales for 6 consecutive years, with 0.8% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales fell 12.0% to 0.8% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.99%, a 12.0% decrease, with the full-year FY2024 number at 0.74%, up 25.0% from a year prior.
  • Return on Sales was 0.8% for Q3 2025 at Vivos Therapeutics, up from 1.31% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 4.52% in Q4 2022 to a low of 1.69% in Q4 2021.
  • A 5-year average of 0.79% and a median of 1.1% in 2024 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: skyrocketed 621bps in 2022, then plummeted -585bps in 2023.
  • Vivos Therapeutics' Return on Sales stood at 1.69% in 2021, then surged by 368bps to 4.52% in 2022, then crashed by -129bps to 1.32% in 2023, then surged by 42bps to 0.76% in 2024, then dropped by -4bps to 0.8% in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Return on Sales are 0.8% (Q3 2025), 1.31% (Q2 2025), and 1.28% (Q1 2025).